The PROfound promise of genomics in mCRPC management
Enzalutamide improves overall survival and delays metastasis in patients with nonmetastatic, castration-resistant prostate cancer: A local case review
A case sharing of apalutamide in the treatment of high risk non-metastatic castration-resistant prostate cancer (nmCRPC) in Hong Kong
Optimizing the diagnosis and management of prostate cancer in Hong Kong
Prostate cancer (PCa) has the highest reported incidence rate among common male cancers in Hong Kong during the past two decades.1 It is the fourth leading cause of cancer-related deaths among males in Hong Kong.
Dr. Poon, Ming-Chun Darren
Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital Honorary Clinical Associate Professor, The Chinese University of Hong Kong
Dr. Joaquin Mateo
Medical Oncologist and Attending Physician, Vall d’Hebron University Hospital, Barcelona Principal Investigator, Prostate Cancer Translational Research Group, Vall d’Hebron Institute of Oncology
Based on the Prostate Cancer Working Group (PCWG) 3 consensus, prostate cancer patients are considered castration-resistant when a minimum rise of 2ng/mL in prostate-specific antigen (PSA) level is observed after androgen depletion therapy (ADT).1 Previously, castration-resistant prostate cancer pat
Dr. Chiu, Ka-Fung Peter
Associate Professor, Department of Surgery, The Chinese University of Hong Kong
Improving beyond current prostate-specific antigen testing to predict prostate cancer
Due to the co-existing prostate-specific antigen (PSA) raising and lowering factors, the commonly used PSA screening test often lacks sufficient sensitivity or specificity to accurately predict prostate cancer (PCa).1 Spermine, a novel non-prostate massage urine biomarker, was recently shown to be
Accelerated approval of erdafitinib: A new treatment option for patients with metastatic bladder cancer
Bladder cancer is the 9th most common malignancy world-wide.1 On April 12, 2019, the U.S. Food and Drug Administration (FDA) approved erdafitinib, a novel personalized treatment targeting genetic alterations of
